Approval · Notice of Compliance 32765 · 2024
BIMZELX: Notice of Compliance 32765
Issued February 23, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32765
- Date
- February 23, 2024
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Nouvelle indication: The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIMZELX | Not yet assigned | — |
Medicinal ingredients
- BIMEKIZUMAB 160 MG per ML
- BIMEKIZUMAB 160 MG per SYR